Zymeworks designates Dr. Kelvin Neu to the board of directors for the advancement of organizational lead product candidates towards commercialization.
FREMONT, CA: A clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, Zymeworks Inc. appoints Kelvin Neu, M.D., to its Board of Directors. Kelvin's clinical knowledge and collaborating expertise help the company advance its lead product candidates towards commercialization.
For more than 16 years, Kelvin has been devoted to finance and build life science companies around the world. Zymeworks is thrilled to welcome Kelvin to the board. The company is sure that it will benefit immensely from an even closer working relationship, with his insights about successful clinical development and experience in working with many companies to bring novel therapies to market. The strength of Zymeworks board reflects its focus on late-stage development and preparation for commercialization in support of the company's goal to meaningfully improve the quality of patients' lives through innovative medicinal culture.
Zymeworks is a clinical-stage biopharmaceutical organization dedicated to the advancement of next-generation multifunctional biotherapeutics. The company's suite of therapeutic platforms and its fully integrated drug development engine facilitate the precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, ZW25, is a unique Azymetric™ bispecific antibody currently in Phase 2 clinical development. The company's second clinical candidate, ZW49, is a bispecific antibody-drug conjugate presently in Phase 1 clinical advancement and combines the unique design and antibody framework of ZW25 with Zymeworks' proprietary ZymeLink™ cytotoxic payload. Zymeworks is advancing a deep preclinical pipeline in oncology (comprising immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being harnessed through strategic partnerships with nine biopharmaceutical firms.